Clinical Trial 50271



<b>Diffuse Cutaneous Systemic Sclerosis (dcSSc) - Multiple Locations in the US</b>

If you have diffuse cutaneous systemic sclerosis (dcSSc), you may be able to take part in a clinical research study.

The purpose of the BEACON Study is to evaluate the effectiveness, safety and tolerability of an investigational medicine compared to a placebo in individuals ages 18 to 75 with diffuse cutaneous systemic sclerosis (dcSSc). The BEACON Study is evaluating if the investigational medicine (HZN-825) may slow disease progression in participants with dcSSc. The investigational medicine is a tablet taken orally twice daily.

All participants who qualify will receive the investigational medicine or a placebo, as well as study-related exams and study-related laboratory tests at no cost. Compensation for time and travel may also be available.

Eligible participants must:

  • Be between 18 and 75 years of age
  • Have a current diagnosis of dcSSc
  • Not be diagnosed with sine scleroderma, limited cutaneous systemic sclerosis, scleroderma renal crisis or other autoimmune connective tissue diseases except for fibromyalgia, scleroderma-associated myopathy and secondary Sjögren’s syndrome
  • Have skin involvement near the elbow or knee
  • Have had less than three years pass since first experiencing systemic sclerosis symptoms, other than Raynaud’s phenomenon

Other protocol-defined inclusion and exclusion criteria may apply.

Available At:

A special website has been created to provide more information about the BEACON Study. The website includes information on what to expect if you are enrolled.

CLICK HERE for more information.


View a list of study sites.


Clinical trials are medical research studies designed to test the safety and/or effectiveness of new investigational drugs, devices, or treatments in humans. These studies are conducted worldwide for a range of conditions and illnesses. Learn more about clinical research and participating in a study at About Clinical Trials.